Ovarian cancer trials in Argentina

In Argentina 10 Also abroad 794

10 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Buenos Aires, Córdoba, Rosario, San Miguel de Tucumán
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Buenos Aires, Capital Federal, Ciudad de Buenos Aires, Córdoba, Rosario, Salta, Santa Fe, Viedma
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Where
Buenos Aires, CABA, Ciudad Autonoma de Buenos Aire, Viedma
Age
18 years and over
People
720 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Buenos Aires, Caba, Ciudad Autonoma Buenos Aires, Mar del Plata
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Enrolling by invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Where
CABA, Córdoba, Rosario
Age
18 years to 51 years
People
250 worldwide
Run by
Tolmar Inc.
See details and how to joinNCT05645536
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Buenos Aires, CABA, Ciudad Autónoma de Buenos Aires, Córdoba, Mar del Plata, Rosario
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Buenos Aires, CABA, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, La Rioja, Mar del Plata, Rosario
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
No phaseTaking people
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Where
Buenos Aires, Ciudad Autonoma de Buenos Aire
Age
18 years and over
People
1,000 worldwide
Run by
AbbVie
See details and how to joinNCT07539844
No phaseNot yet taking people in Argentina
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
Where
Buenos Aires, Rosario
Age
18 years and over
People
320 worldwide
Run by
Latin American Cooperative Oncology Group
See details and how to joinNCT07771400
No phaseTaking people
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Where
Rosario
Age
40 years to 75 years
People
6,000 worldwide
Run by
Javier Toledo
See details and how to joinNCT06717295